Which antibiotic has been shown to contribute to drug-resistant pneumococcal infections in smokers when used as first-line therapy?

• A. Clarithromycin
• B. Doxycycline
• C. Augmentin
• D. Levofloxacin

Answer: (D)

The key idea is that using antibiotics can select for resistant bacteria, especially in people who carry Streptococcus pneumoniae. Smokers have a higher carriage rate of pneumococcus, and the strains they carry are more likely to be resistant. When a fluoroquinolone like levofloxacin is used as first-line therapy, it applies strong selective pressure on pneumococcus. Mutations that reduce drug binding in targets such as DNA gyrase and topoisomerase IV can quickly make the bacteria less susceptible, so resistant pneumococcal strains become more common and can cause infection. This is why levofloxacin, though effective, is linked to promoting drug-resistant pneumococcal infections when used as initial therapy in smokers, and why guidelines emphasize caution with fluoroquinolones as first-line agents in this context.